The authors report preliminary results of 10 patients participating in a multicentric international study, into the efficacy and safety of the GnRH antagonist Cetrorelix in women undergoing controlled ovarian stimulation for IVF/ICSI treatment. Results suggest that co-treatment with GnRH antagonist Cetrorelix decreases the duration of stimulation, the number of gonadotropin ampoules used and the prevalence of hyperstimulation syndrome without compromising the number and quality of oocytes or preembryos and the fertilization or pregnancy rate, compared to stimulation with 'conventional' GnRH agonist + gonadotropin regimen. These encouraging results may be due to the improved endocrine milieu (prevention of premature LH surge and gradual incrase of serum estradiol concentration) as seen during 'conventional' GnRH agonist + gonadotropin cycles. The authors are the first in Hungary to report on clinical pregnancies with the use of GnRH antagonist Cetrorelix.
|Translated title of the contribution||Preliminary results with the use of the GnRH antagonist Cetrorefix in in-vitro fertilization treatment|
|Number of pages||7|
|Journal||Magyar Noorvosok Lapja|
|Publication status||Published - Jan 1 2000|
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynaecology